Critical Review: LivaNova PLC (LIVN) & (EVAR)

LivaNova PLC (NASDAQ: LIVN) and (NASDAQ:EVAR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.

Institutional and Insider Ownership

81.8% of LivaNova PLC shares are held by institutional investors. 0.3% of LivaNova PLC shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for LivaNova PLC and , as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LivaNova PLC 1 2 4 0 2.43
0 0 0 0 N/A

LivaNova PLC presently has a consensus price target of $76.83, indicating a potential downside of 8.88%.


This table compares LivaNova PLC and ‘s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LivaNova PLC 4.63% 9.33% 6.82%

Valuation & Earnings

This table compares LivaNova PLC and ‘s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
LivaNova PLC $1.21 billion 3.35 -$62.78 million $1.17 72.07

has higher revenue, but lower earnings than LivaNova PLC.


LivaNova PLC beats on 7 of the 7 factors compared between the two stocks.

LivaNova PLC Company Profile

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.

Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with's FREE daily email newsletter.

Leave a Reply